Literature DB >> 10066662

Predictive value of CD19 measurements for bacterial infections in children infected with human immunodeficiency virus.

R A Betensky1, T Calvelli, S Pahwa.   

Abstract

We investigated the predictive value of CD19 cell percentages (CD19%) for times to bacterial infections, using data from six pediatric AIDS Clinical Trials Group protocols and adjusting for other potentially prognostic variables, such as CD4%, CD8%, immunoglobulin (IgA) level, lymphocyte count, prior infections, prior zidovudine treatment, and age. In addition, we explored the combined effects of CD19% and IgG level in predicting time to infection. We found that a low CD19% is associated with a nonsignificant 1.2-fold increase in hazard of bacterial infection (95% confidence interval: 0.97, 1.49). In contrast, a high IgG level is associated with a nonsignificant 0.87-fold decrease in hazard of infection (95% confidence interval: 0.68, 1.12). CD4% was more prognostic of time to bacterial infection than CD19% or IgG level. Low CD19% and high IgG levels together lead to a significant (P < 0. 01) 0.50-fold decrease in hazard (95% confidence interval: 0.35, 0. 73) relative to low CD19% and low IgG levels. Similarly, in a model involving assay result changes (from baseline to 6 months) as well as baseline values, the effect of CD19% by itself is reversed from its effect in conjunction with IgG. In this model, CD19% that are increasing and high are associated with decreases in hazard of infection (P < 0.01), while increasing CD19% and increasing IgG levels are associated with significant (at the P = 0.01 level) fourfold increases in hazard of infection relative to stable CD19% and decreasing, stable, or increasing IgG levels. Our data suggest that CD19%, in conjunction with IgG level, provides a useful prognostic tool for bacterial infections. It is highly likely that T-helper function impacts on B-cell function; thus, inclusion of CD4% in such analyses may greatly enhance the assessment of risk for bacterial infection.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10066662      PMCID: PMC95695          DOI: 10.1128/CDLI.6.2.247-253.1999

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  12 in total

Review 1.  Intravenous immune globulin in patients with acquired immune deficiency syndrome.

Authors:  S Pahwa
Journal:  J Allergy Clin Immunol       Date:  1989-10       Impact factor: 10.793

2.  Low number of functionally active B lymphocytes in the peripheral blood of HIV-1-seropositive individuals with low p24-specific serum antibody titers.

Authors:  V J Teeuwsen; J M Lange; R Keet; J K Schattenkerk; C Debouck; R van den Akker; J Goudsmit; A D Osterhaus
Journal:  AIDS       Date:  1991-08       Impact factor: 4.177

3.  Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection.

Authors: 
Journal:  N Engl J Med       Date:  1991-07-11       Impact factor: 91.245

4.  Peripheral B-cell activation and immaturity in HIV-infected children.

Authors:  C Rodriguez; E R Stiehm; S Plaeger-Marshall
Journal:  Ann N Y Acad Sci       Date:  1993-10-29       Impact factor: 5.691

5.  Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1.

Authors:  J M Binley; P J Klasse; Y Cao; I Jones; M Markowitz; D D Ho; J P Moore
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

6.  Immune defects in pediatric AIDS, their pathogenesis, and role of immunotherapy.

Authors:  S Pahwa
Journal:  Crit Care Med       Date:  1990-02       Impact factor: 7.598

7.  Immunoglobulin VH3 gene products: natural ligands for HIV gp120.

Authors:  L Berberian; L Goodglick; T J Kipps; J Braun
Journal:  Science       Date:  1993-09-17       Impact factor: 47.728

8.  Ontogeny of anti-human immunodeficiency virus (HIV) antibody production in HIV-1-infected infants.

Authors:  H Pollack; M X Zhan; T Ilmet-Moore; K Ajuang-Simbiri; K Krasinski; W Borkowsky
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-15       Impact factor: 11.205

9.  Spontaneous in vitro production of virus-specific antibody by lymphocytes from HIV-infected subjects.

Authors:  A Amadori; A De Rossi; G P Faulkner-Valle; L Chieco-Bianchi
Journal:  Clin Immunol Immunopathol       Date:  1988-03

10.  Defective humoral immunity in pediatric acquired immune deficiency syndrome.

Authors:  L J Bernstein; H D Ochs; R J Wedgwood; A Rubinstein
Journal:  J Pediatr       Date:  1985-09       Impact factor: 4.406

View more
  3 in total

1.  Persistently high IgA serum levels are a marker of immunological or virological failure of combined antiretroviral therapy in children with perinatal HIV-1 infection.

Authors:  Elena Chiappini; Luisa Galli; Pier-Angelo Tovo; Clara Gabiano; Maurizio de Martino
Journal:  Clin Exp Immunol       Date:  2005-05       Impact factor: 4.330

2.  Prospective 5-year study of peripheral blood CD4, CD8, and CD19/CD20 lymphocytes and serum Igs in children born to HIV-1 women. The P(2)C(2) HIV Study Group.

Authors:  W T Shearer; K A Easley; J Goldfarb; H M Rosenblatt; H B Jenson; A Kovacs; K McIntosh
Journal:  J Allergy Clin Immunol       Date:  2000-09       Impact factor: 10.793

3.  Evaluation of immune survival factors in pediatric HIV-1 infection.

Authors:  W T Shearer; K A Easley; J Goldfarb; H B Jenson; H M Rosenblatt; A Kovacs; K McIntosh
Journal:  Ann N Y Acad Sci       Date:  2000-11       Impact factor: 5.691

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.